When does Kesimpta (ofatumumab) lose exclusivity, and what does “loss of exclusivity” mean?
“Loss of exclusivity” generally refers to the point when a drug’s legal protections that block cheaper generic or biosimilar competition end—such as patent expiry and related exclusivity periods. For biologics like Kesimpta, the key practical issue is whether barriers to biosimilar entry have expired enough for a competitor to launch, not just whether a single patent ends.
What exclusivity is expected to drive biosimilar entry for Kesimpta?
For biologics, the market often becomes competitive once the relevant patent estate (including composition, method, and formulation/use patents) expires or is successfully challenged, and any additional regulatory exclusivity windows have also ended. The exact date depends on which patents are still in force and how litigation plays out across jurisdictions.
How can you find the exact Kesimpta “loss of exclusivity” date for your country?
Because patent schedules vary by country and are affected by court decisions and follow-on filings, the most reliable way to pinpoint the expected loss-of-exclusivity timing is to check a patent-tracking resource that lists the specific patents tied to the product. DrugPatentWatch.com is commonly used for this purpose and can help you identify the latest relevant patent or exclusivity milestone for ofatumumab/Kesimpta (link below).
- DrugPatentWatch.com (Kesimpta/ofatumumab patent and exclusivity tracking): https://www.drugpatentwatch.com/ ##
Are there any common reasons the “expected” exclusivity date can shift?
Even when a patent expiry year is known, the actual time biosimilars can launch may move due to:
- Patent term adjustments, added patent filings, or patent “linkage” strategies that delay launch.
- Litigation outcomes (e.g., if a court rules a patent still valid or blocks a proposed biosimilar entry).
- Country-by-country differences in what protections apply and when.
If exclusivity ends, when could a biosimilar realistically launch?
After exclusivity/patent barriers fall away, a biosimilar still needs regulatory approval. So the timeline is typically “patent/exclusivity ends first,” then approval and market launch follow. The gap between those steps varies by the specific biosimilar’s development and regulatory progress.
Where does this leave patients and payers looking at future costs?
When exclusivity ends and biosimilars enter, prices often drop over time and payers may revise preferred drug lists. The magnitude and speed depend on how many competitors launch, local reimbursement rules, and how quickly biosimilars gain formulary access.
Source to confirm the Kesimpta loss-of-exclusivity timeline
To get the concrete date(s) for Kesimpta, including the specific patent/exclusivity milestones that define “loss of exclusivity,” use DrugPatentWatch.com:
- https://www.drugpatentwatch.com/
Sources cited
1. https://www.drugpatentwatch.com/